Loading
Medios AG Stock: price and insider trades · Germany
1 insider bought €39k of shares over the last 90 days, the latest filed 13 Aug 2026.
Medios AG: what insiders have been doing
Medios AG is a Healthcare & Pharma company based in Berlin, Germany. Its directors and officers file their transactions with BaFin. Between 18 October 2025 and 18 October 2026, 3 insiders published 3 filings.
Only purchases show up on the open market, 2 purchases in all worth €99k, filed by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €60k from Prusseit, Christoph, disclosed on 22 January 2026. Among those who bought: 2 senior executives.
The last insider purchase was made public on 13 August 2026, 65 days ago. Between a trade and the moment it shows up on BaFin, the median delay is 1 day. The legal deadline for notifying a trade is three business days (MAR article 19).
Across the 287 companies tracked on its exchange, the median is 5 filings; at 3 filings, this issuer sits below that mark. Since 2026, the database holds 2 purchases and no sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Key facts
Headquarters: Berlin, Germany
Source: Wikidata (CC0).
Insider Decl.
3
Thresholds
n/a
Buy Volume
€98,788
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleChristoph Prusseit2 buys
Stefan Bauerreis1 buy
Since the insiders bought
- -6.4%Entry €10.96 · Close at T+30 €10.26
- -38.4%Entry €16.42 · Close 16 Oct 2026 €10.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Medios AG Strong Buy (bullish), based on 4 analysts. Average price target: €20.25.
Fundamental score
Ranked 9,985 of 24,148 companies
55.9
score / 100
Value83
Quality29
FCF yld17%
Earn yld5.8%
EV/EBITDA5.3x
ROE2.1%
Gross mgn9.6%
Net mgn0.7%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€10.32
Analyst consensus
4 analystsStrong buy
€16.00Target €20.25(+96%)€23.00
Income statement
Revenue€2.1B
Gross profit€199.2M10% margin
EBITDA€84.9M4% margin
Net income€15.4M0.5% margin
Valuation
PER (trailing)22.9x
PER (forward)6.8x
P/Book0.5x
Beta1.26
Balance sheet & cash
Market cap€263.2M
Total debt€189.1M
Free Cash Flow€44.0M
Debt / Equity38%
Profitability & ownership
ROE2.1%
ROA2.6%
% insiders19.7%
% institutions47.7%
Last declaration on 13 August 2026
Declarations3 total
3,499.412 shares@ €11.130.014% mcap100.0% of flowShareXetraISIN DE000A1MMCC8BAFIN:40000313-e1b903b1bd1f
Canonical exit: 10 Nov 2026 (T+90)
13,638 shares@ €16.00100.0% of flowShareISIN DE000A1MMCC8BAFIN:40000313-8104fc199dab
4,000 shares@ €14.96100.0% of flowShareXETRAISIN DE000A1MMCC8BAFIN:40000313
Canonical exit: 21 Apr 2026 (T+90)
3 of 3 declarations
About Medios AG
Medios AG is a healthcare and specialty pharma company listed in Germany, with shares traded on Xetra/Frankfurt (DAX/MDAX/SDAX). For French-speaking investors, it is best understood as a leading European specialty-pharma platform focused on complex medicines and individualized therapies. Medios describes itself as Germany’s first listed specialty pharmaceutical company, and its registered office is in Berlin, Germany. ([medios.ag](https://medios.ag/en/news-detail-view/medios-ag-records-further-revenue-growth-in-the-first-quarter-of-2024-and/64?cHash=c659e5e08276107feb799b69126e2ee7&utm_source=openai))
The group’s business model is built around specialty pharmaceutical supply and patient-specific compounding. In practical terms, Medios serves pharmacies, specialist medical practices, and pharmaceutical companies, helping make innovative therapies available in areas such as rare, chronic, or highly individualized treatments. This business requires strict regulatory compliance, reliable cold-chain and logistics capabilities, and deep know-how in the handling of high-complexity pharmaceutical products. ([medios.ag](https://medios.ag/en/news-detail-view/medios-ag-records-further-revenue-growth-in-the-first-quarter-of-2024-and/64?cHash=c659e5e08276107feb799b69126e2ee7&utm_source=openai))
Read moreShow less
From a historical perspective, Medios developed in Germany as a focused specialty-pharma specialist and has since broadened its footprint through M&A. A major inflection point came in 2024 with the completion of the acquisition of Ceban Pharmaceuticals, which expanded Medios’ reach into the Netherlands, Belgium, and Spain through a fast-growing compounding platform. That transaction materially strengthened the company’s European market position and increased its scale in a still-fragmented niche. ([medios.ag](https://medios.ag/en/news-detail-view/medios-ag-successfully-completes-acquisition-of-ceban-significantly-expanding/64?cHash=c659e5e08276107feb799b69126e2ee7&utm_source=openai))
Geographically, Medios remains firmly anchored in Germany, but it now operates on a more international European basis. Its core markets benefit from growing demand for personalized medicine, secure specialty-drug supply, and outsourced pharmaceutical services. Medios’ competitive edge comes from combining distribution, compounding, and pharmaceutical expertise in one integrated platform, which differentiates it from a standard wholesaler. ([medios.ag](https://medios.ag/en/news-detail-view/medios-ag-successfully-completes-acquisition-of-ceban-significantly-expanding/64?cHash=c659e5e08276107feb799b69126e2ee7&utm_source=openai))
Recent company developments point to continued operational momentum. In 2025, Medios reported improving profitability and cash flow in interim results and reaffirmed its full-year outlook. The company also announced that Thomas Meier will take over as CEO on February 1, 2026. In addition, Medios executed and successfully completed a public share buyback offer in 2025, which signals management confidence and supports the capital-allocation story. ([medios.ag](https://medios.ag/newsdetailview/medios-ag-erzielt-kraeftiges-wachstum-von-ergebnis-und-ergebnismarge-im/50?cHash=b4dc1085513752733b2ed16edc8be503&utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
